Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SAP SE (SAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs SAP SE — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while SAP SE trades at $157.5 (market cap $191.33B). The key difference: SAP SE is far larger — about 42.6× ACADIA Pharmaceuticals Inc.'s market cap, and SAP SE pays a 1.8% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SAP | |
|---|---|---|
Market Cap | $4.49B | $191.33B |
Sector | Health | Technology |
52-Week High | $28.06 | $311.93 |
52-Week Low | $20.06 | $148.06 |
Enterprise Value | $3.69B | $188.85B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SAP trades at $162.77, up 0.11% with recent earnings beats driving positive momentum. The stock shows strong fundamentals with 19.58% net margins and consistent revenue growth to $36.8B in 2025. Technical indicators are mixed with bearish moving averages but neutral oscillators, while analyst consensus remains bullish with a $228.50 price target representing 40% upside potential from current levels.
SAP presents a compelling investment case with robust profitability and strategic AI investments, though near-term technical weakness and competitive pressures from Oracle's AI spending create headwinds. The company's cloud transition progress and strong cash flow generation support long-term growth prospects despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
